A phase II study of sunitinib in patients with recurrent and/or metastatic non-nasopharyngeal head and neck cancer

Cancer Chemotherapy and Pharmacology

Volumn 65, Issue 4, 2010, Pages 649-660

  Fountzilas, George ^a   Fragkoulidi, Anna ^a   Kalogera Fountzila, Anna ^a   Nikolaidou, Martha ^b   Bobos, Mattheos ^a   Calderaro, Julien ^c   Andreiuolo, Felipe ^c   Marselos, Marios ^b  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b UNIVERSITY OF IOANNINA   (Greece)

^c INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Angiogenesis; Head and neck cancer; Pharmacokinetic analysis; Sunitinib

Indexed keywords

ANTIEMETIC AGENT; LOPERAMIDE; SUNITINIB; ANGIOGENESIS INHIBITOR; HIF1A PROTEIN, HUMAN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INDOLE DERIVATIVE; PYRROLE DERIVATIVE; SU 12662; VASCULOTROPIN A;

ADULT; AGED; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLEEDING; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; COUGHING; DIARRHEA; DIZZINESS; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG WITHDRAWAL; DYSPHAGIA; FATIGUE; FEMALE; FEVER; HEAD AND NECK CANCER; HUMAN; HYPERAMYLASEMIA; HYPERURICEMIA; HYPOPHOSPHATEMIA; INFECTION; LEUKOPENIA; LIQUID CHROMATOGRAPHY; LYMPHOCYTOPENIA; MALE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MOOD CHANGE; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUTROPENIA; PAIN; PANCREATITIS; PRIORITY JOURNAL; PROGNOSIS; RASH; RECURRENT CANCER; SIDE EFFECT; SKIN DISCOLORATION; SOMNOLENCE; SQUAMOUS CELL CARCINOMA; STOMATITIS; TANDEM MASS SPECTROMETRY; TASTE DISORDER; THROMBOCYTOPENIA; TRACHEOESOPHAGEAL FISTULA; AREA UNDER THE CURVE; BLOOD; CHEMICALLY INDUCED DISORDER; DRUG ADMINISTRATION; HEAD AND NECK TUMOR; IMMUNOHISTOCHEMISTRY; METABOLIC CLEARANCE RATE; METABOLISM; METASTASIS; MIDDLE AGED; PATHOLOGY; PHASE 2 CLINICAL TRIAL; SURVIVAL; TREATMENT OUTCOME; TUMOR RECURRENCE;

AGED; ANGIOGENESIS INHIBITORS; ANOREXIA; AREA UNDER CURVE; CARCINOMA, SQUAMOUS CELL; DRUG ADMINISTRATION SCHEDULE; FATIGUE; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOHISTOCHEMISTRY; INDOLES; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PYRROLES; SURVIVAL ANALYSIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 75749105462     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-009-1070-1     Document Type: Article

References (33)

1. J Ferlay P Autier M Boniol M Heanue M Colombet P Boyle 2007 Estimates of the cancer incidence and mortality in Europe in 2006 Ann Oncol 18 3 581 592 10.1093/annonc/mdl498 1:STN:280:DC%2BD2s7hslSgtw%3D%3D 17287242 (Pubitemid 46359643)
2. A Jemal R Siegel E Ward T Murray J Xu MJ Thun 2007 Cancer statistics CA Cancer J Clin 57 1 43 66 10.3322/canjclin.57.1.43 17237035
3. AD Colevas 2006 Chemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neck J Clin Oncol 24 17 2644 2652 10.1200/JCO.2005.05.3348 1:CAS:528:DC%2BD28XmslSisb8%3D 16763278 Review (Pubitemid 46628471)
4. PM Specenier JB Vermorken 2008 Recurrent head and neck cancer: current treatment and future prospects Exp Rev Anticancer Ther 8 3 375 391 10.1586/14737140.8.3.375 1:CAS:528:DC%2BD1cXjvF2ltbs%3D (Pubitemid 351836286)
5. JB Vermorken R Mesia F Rivera E Remenar A Kawecki S Rottey J Erfan D Zabolotnyy HR Kienzer D Cupissol F Peyrade M Benasso I Vynnychenko D De Raucourt C Bokemeyer A Schueler N Amellal R Hitt 2008 Platinum-based chemotherapy plus cetuximab in head and neck cancer N Engl J Med 359 11 1116 1127 10.1056/NEJMoa0802656 1:CAS:528:DC%2BD1cXhtFWrsrnI 18784101
6. LQ Chow SG Eckhardt 2007 Sunitinib: from rational design to clinical efficacy J Clin Oncol 25 7 884 896 10.1200/JCO.2006.06.3602 1:CAS:528: DC%2BD2sXjvVKmtLY%3D 17327610 (Pubitemid 350002890)
7. M Beeram A Patnaik EK Rowinsky 2005 Raf: a strategic target for therapeutic development against cancer J Clin Oncol 23 27 6771 6790 10.1200/JCO.2005.08.036 1:CAS:528:DC%2BD2MXhtFWqsb7P 16170185 (Pubitemid 46194105)
8. N Ferrara RS Kerbel 2005 Angiogenesis as a therapeutic target Nature 438 7070 967 974 10.1038/nature04483 1:CAS:528:DC%2BD2MXhtlSksrnI 16355214 (Pubitemid 43093963)
9. DJ Hicklin LM Ellis 2005 Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis J Clin Oncol 23 5 1011 1027 10.1200/JCO.2005.06.081 1:CAS:528:DC%2BD2MXit1Gnsro%3D 15585754 (Pubitemid 46202320)
10. PA Kyzas IW Cunha JP Ioannidis 2005 Prognostic significance of vascular endothelial growth factor immunohistochemical expression in head and neck squamous cell carcinoma: a meta-analysis Clin Cancer Res 11 4 1434 1440 10.1158/1078-0432.CCR-04-1870 1:CAS:528:DC%2BD2MXhvVSrsLg%3D 15746043 (Pubitemid 40315223)
11. S Ninck C Reisser G Dyckhoff B Helmke H Bauer C Herold-Mende 2003 Expression profiles of angiogenic growth factors in squamous cell carcinomas of the head and neck Int J Cancer 106 1 34 44 10.1002/ijc.11188 1:CAS:528:DC%2BD3sXltFent7g%3D 12794754 (Pubitemid 36750385)
12. PA Kyzas D Stefanou A Batistatou NJ Agnantis 2005 Potential autocrine function of vascular endothelial growth factor in head and neck cancer via vascular endothelial growth factor receptor-2 Mod Pathol 18 4 485 494 10.1038/modpathol.3800295 1:CAS:528:DC%2BD2MXisVSht7g%3D 15475932 (Pubitemid 40478111)
13. C Neuchrist BM Erovic A Handisurya MB Fischer GE Steiner D Hollemann C Gedlicka A Saaristo M Burian 2003 Vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 expression in squamous cell carcinomas of the head and neck Head Neck 25 6 464 474 10.1002/hed.10235 12784238 (Pubitemid 36577031)
14. RJ Motzer MD Michaelson BG Redman GR Hudes G Wilding RA Figlin MS Ginsberg ST Kim CM Baum SE DePrimo JZ Li CL Bello CP Theuer DJ George BI Rini 2006 Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma J Clin Oncol 24 1 16 24 10.1200/JCO.2005.02.2574 1:CAS:528:DC%2BD28Xot1ChtA%3D%3D 16330672 (Pubitemid 46630489)
15. M Miettinen LH Sobin J Lasota 2005 Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1,765 cases with long-term follow-up Am J Surg Pathol 29 1 52 68 10.1097/01.pas.0000146010.92933.de 15613856 (Pubitemid 40023952)
16. AM Jubb TQ Pham AM Hanby GD Frantz FV Peale TD Wu HW Koeppen KJ Hillan 2004 Expression of vascular endothelial growth factor, hypoxia inducible factor 1 alpha, and carbonic anhydrase IX in human tumours J Clin Pathol 57 5 504 512 10.1136/jcp.2003.012963 1:CAS:528:DC%2BD2cXmtl2qurk%3D 15113858 (Pubitemid 38621796)
17. SP Gunningham MJ Currie C Han BA Robinson PA Scott AL Harris SB Fox 2000 The short form of the alternatively spliced flt-4 but not its ligand vascular endothelial growth factor C is related to lymph node metastasis in human breast cancers Clin Cancer Res 6 11 4278 4286 1:CAS:528:DC%2BD3cXovVSgur8%3D 11106244
18. S Faivre C Delbaldo K Vera C Robert S Lozahic N Lassau C Bello S Deprimo N Brega G Massimini JP Armand P Scigalla E Raymond 2006 Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer J Clin Oncol 24 1 25 35 10.1200/JCO.2005.02. 2194 1:CAS:528:DC%2BD28Xot1ChtQ%3D%3D 16314617 (Pubitemid 46630490)
19. CL Bello L Sherman J Zhou L Verkh J Smeraglia J Mount KJ Klamerus 2006 Effect of food on the pharmacokinetics of sunitinib malate (SU11248), a multi-targeted receptor tyrosine kinase inhibitor: results from a phase I study in healthy subjects Anticancer Drugs 17 3 353 358 10.1097/00001813-200603000- 00015 1:CAS:528:DC%2BD28XitVGnur8%3D 16520665
20. Choong NW (2008) Phase II trial of sunitinib in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol 26 (abstr 6064)
21. PA Kyzas D Stefanou NJ Agnantis 2004 Immunohistochemical expression of vascular endothelial growth factor correlates with positive surgical margins and recurrence in T1 and T2 squamous cell carcinoma (SCC) of the lower lip Oral Oncol 40 9 941 947 10.1016/j.oraloncology.2004.04.018 1:CAS:528: DC%2BD2cXnslGnt74%3D 15380173 (Pubitemid 39369567)
22. R Hitt A Jimeno M Rodríguez-Pinilla JL Rodríguez-Peralto JM Millán A López-Martín A Brandariz C Peña H Cortés-Funes 2004 Phase II trial of cisplatin and capecitabine in patients with squamous cell carcinoma of the head and neck, and correlative study of angiogenic factors Br J Cancer 91 12 2005 2011 10.1038/sj.bjc.6602275 1:CAS:528:DC%2BD2cXhtVOjsLfL 15597103 (Pubitemid 40128766)
23. WM Ongkeko X Altuna RA Weisman J Wang-Rodriguez 2005 Expression of protein tyrosine kinases in head and neck squamous cell carcinomas Am J Clin Pathol 124 1 71 76 10.1309/BTLN5WTMJ3PCNRRC 1:CAS:528:DC%2BD2MXmvVGntr8%3D 15923166
24. C Elser LL Siu E Winquist M Agulnik GR Pond SF Chin P Francis R Cheiken J Elting A McNabola D Wilkie O Petrenciuc EX Chen 2007 Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma J Clin Oncol 25 24 3766 3773 10.1200/JCO.2006.10.2871 1:CAS:528:DC%2BD2sXhtVeqtL7N 17704426 (Pubitemid 47372619)
25. M Miyahara J Tanuma K Sugihara I Semba 2007 Tumor lymphangiogenesis correlates with lymph node metastasis and clinicopathologic parameters in oral squamous cell carcinoma Cancer 110 6 1287 1294 10.1002/cncr.22900 17674352 (Pubitemid 47435600)
26. Y Tanigaki Y Nagashima Y Kitamura H Matsuda Y Mikami M Tsukuda 2004 The expression of vascular endothelial growth factor-A and -C, and receptors 1 and 3: correlation with lymph node metastasis and prognosis in tongue squamous cell carcinoma Int J Mol Med 14 3 389 395 1:CAS:528:DC%2BD2cXntlWgtLc%3D 15289890
27. G Bergers D Hanahan 2008 Modes of resistance to anti-angiogenic therapy Nat Rev Cancer 8 8 592 603 10.1038/nrc2442 1:CAS:528:DC%2BD1cXovV2lsrk%3D 18650835
28. LB Saltz LS Rosen JL Marshall RJ Belt HI Hurwitz SG Eckhardt EK Bergsland DG Haller AC Lockhart CM Rocha Lima X Huang SE DePrimo E Chow-Maneval RC Chao HJ Lenz 2007 Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy J Clin Oncol 25 30 4793 4799 10.1200/JCO.2007.12.8637 1:CAS:528:DC%2BD2sXhtlCgsLbI 17947727 (Pubitemid 350086483)
29. HJ Burstein AD Elias HS Rugo MA Cobleigh AC Wolff PD Eisenberg M Lehman BJ Adams CL Bello SE DePrimo CM Baum KD Miller 2008 Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane J Clin Oncol 26 11 1810 1816 10.1200/JCO.2007.14.5375 1:CAS:528: DC%2BD1cXmsFemsb8%3D 18347007
30. MA Socinski S Novello JR Brahmer R Rosell JM Sanchez CP Belani R Govindan JN Atkins HH Gillenwater C Pallares L Tye P Selaru RC Chao GV Scagliotti 2008 Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer J Clin Oncol 26 4 650 656 10.1200/JCO.2007.13.9303 1:CAS:528:DC%2BD1cXis1alsbs%3D 18235126 (Pubitemid 351264362)
31. DB Mendel AD Laird X Xin SG Louie JG Christensen G Li RE Schreck TJ Abrams TJ Ngai LB Lee LJ Murray J Carver E Chan KG Moss JO Haznedar J Sukbuntherng RA Blake L Sun C Tang T Miller S Shirazian G McMahon JM Cherrington 2003 In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship Clin Cancer Res 9 1 327 337 1:CAS:528:DC%2BD3sXnt1OrtA%3D%3D 12538485 (Pubitemid 36109749)
32. P Silva NJ Slevin P Sloan H Valentine J Cresswell D Ryder P Price JJ Homer CM West 2008 Prognostic significance of tumor hypoxia inducible factor-1alpha expression for outcome after radiotherapy in oropharyngeal cancer Int J Radiat Oncol Biol Phys 72 5 1551 1559 1:CAS:528:DC%2BD1cXhsVWlsL7I 19028277
33. M Kappler H Taubert HJ Holzhausen R Reddemann S Rot A Becker T Kuhnt K Dellas J Dunst D Vordermark G Hänsgen M Bache 2008 Immunohistochemical detection of HIF-1alpha and CAIX in advanced head-and-neck cancer prognostic role and correlation with tumor markers and tumor oxygenation parameters Strahlenther Onkol 184 8 393 399 10.1007/s00066-008-1813-7 18956515